Alliances are not enough explaining rapid growth in biotechnology firms

By Jorge Niosi. 2003

230 citations recorded by the source corpus.

Subfields: Economics and Econometrics, Management of Technology and Innovation, Strategy and Management

View Paper: https://www.semanticscholar.org/paper/4795bc2bde7d834790417ce0a3876541a5d15d7e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Economics and Econometrics

1. C. Baden-Fuller
2. Elicia Maine
3. Pek Hooi Soh
4. Nancy Dos Santos
5. P. Namara

In Management of Technology and Innovation

1. C. Baden-Fuller
2. Elicia Maine
3. Pek Hooi Soh
4. Nancy Dos Santos
5. P. Namara

In Strategy and Management

1. C. Baden-Fuller
2. Elicia Maine
3. Pek Hooi Soh
4. P. Namara
5. Chander K. Velu
6. Dennis M. Steininger

Citations in the corpus

• Shareholder returns and the exploration–exploitation dilemma: R&D announcements by biotechnology firms (2007, background): “…it enables the firm to have the option of negotiatingR&Dandcommercializationdealswith collaborative partners in amore secure long-termappropriation regime (Cohen et al., 2002), and it also signals to the financial community the novelty and promise of their exploration activities (Niosi, 2003).”
• The role of entrepreneurial decision-making in opportunity creation and recognition (2015, background): “…entrepreneurs operate under challenging conditions, with sustained levels of high technology and market uncertainty, high levels of capital investment, and stringent regulatory requirements during clinical development (DiMasi et al., 2003; Liebeskind et al., 1996; Niosi, 2003; Pisano, 2006, 2010).”